19 results about "HY Antigen" patented technology

A major challenge in the field of antibody-based therapeutics is the development of antibodies that have longer duration of action, longer half-life and can be delivered to a patient at lower doses. The current methods to achieve this aim depend on the engineering modification of the pH-dependent antigen binding properties of the antibodies, which is very strenuous and generally requires further optimization of the pH-sensitive interactions in a low-throughput, individualized manner because these methods depend mainly on the introduction of histidine mutations in specific antibody complementarity determining regions (CDRs). In the present invention, the inventors provide antibodies and other antigen-binding proteins that carry mutations outside of the complementals, thereby conferring universal pH-sensitive binding properties to the antibodies. The invention also relates to methods of isolating and generating said antigen binding proteins, compositions and medical uses thereof.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention describes immunogenic compositions containing immunogenic polypeptides of Porcine circovirus 2e, 3c, or 4 (PCV2e, PCV3c, or PCV4), including immunogenic compositions containing antigens other than PCV2e, PCV3c, or PCV4 antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating a PCV2e, PCV3c, or PCV4 infection are also described.

The present invention provides anti-CD73 binding molecules, such as antibodies and their antigen-binding fragments. [Solution] Provided are isolated binding molecules or antigen-binding fragments thereof that contain an antibody VL and specifically bind to CD73 having a specific sequence. Furthermore, pharmaceutical formulations comprising the disclosed composition, as well as methods for diagnosing and treating diseases associated with CD73 expression, such as cancer, are also provided. Such diseases can be treated, for example, by direct therapy with the disclosed anti-CD73 binding molecule (e.g., a naked antibody or antibody-drug conjugate that binds to CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and / or by combination therapy in which the anti-CD73 molecule is administered before, after, or concurrently with chemotherapy.

The present invention relates to an antibody fragment consisting of only the constant region of an antibody, and more particularly to an antibody fragment having no variable region of an antibody and consisting of only a heavy chain constant region (C H ) and a light chain constant region (C L ). For example, the present invention relates to an antibody fragment consisting of a heavy chain constant region and a light chain constant region (IgCw-gamma1epsilon2-4 / kappa), in which a gamma constant region (Cgamma1) and an epsilon constant region (Cepsilon2-4) are fused; a nucleic acid encoding the antibody fragment; a kit comprising the antibody fragment; and a use of the antibody fragment. In order to evaluate the efficacy of an antibody in the development of a new antibody drug or the like, a control, i.e., a reference antibody, is required, and the existing reference antibody cannot be completely free from non-specific binding, i.e., off-target effects due to reactions with other antigens, and the purification yield is also low. On the other hand, when the recombinant protein IgCw-gamma1epsilon2-4 / kappa consisting of only the constant region of an antibody according to the present invention is used, the problems of the existing reference antibody can be overcome, and the recombinant protein can also be used as an Fc epsilon receptor inhibitor that inhibits an allergic reaction. Therefore, the IgCw-gamma1epsilon 2‑4 / kappa according to the present invention can be used in various ways in the field of biomedical science.

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and / or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for detecting anti-DLAT autoantibody in preparation of a product for detecting and / or diagnosing immune-mediated necrotizing myopathy. Experiments prove that DLAT can be used as a recognition antigen of an immune-mediated necrotizing myopathy related autoantibody, DLAT is a target point of the immune-mediated necrotizing myopathy autoantibody, the reactivity of the anti-DLAT autoantibody with the related antigen in dermatomyositis is 0%, the reactivity of the anti-DLAT autoantibody with other antigens HMGCR and SRP of the immune-mediated necrotizing myopathy is 0%, the anti-DLAT autoantibody is a new biological marker of the immune-mediated necrotizing myopathy, and the immune-mediated necrotizing myopathy can be detected and / or diagnosed.

The application relates to a preparation method of a low-potential near-infrared electrochemiluminescence immunosensor taking t-butylamine-borane as a co-reagent. The application relates to a preparation of a low-potential near-infrared electrochemiluminescence (about 0.57 V vs Ag / AgCl) immunosensor, mainly including (1) a preparation method of water-soluble gold nanoclusters (Cit / MSA@Au NCs) capable of generating low-potential near-infrared electrochemiluminescence, taking double ligand citrate and thiomalic acid as stabilizers, (2) preparation of gold nanocluster-labeled secondary antibody (Cit / MSA@Au|Ab2), (3) preparation of a low-potential near-infrared electrochemiluminescence sensor based on a sandwich immunization principle and taking gold nanoclusters as a label, and (4) drawing of a working curve. The prepared low-potential near-infrared electrochemiluminescence immunosensor has high detection sensitivity, and other antigen proteins do not interfere with the sensing and detection of the target antigen of the application.

The present invention relates to antibodies or other antigen binding proteins targeting the CD276 antigen also known as B7-H3. The present invention provides improved antibody collections that bind to novel positions within the CD276 antigen and are particularly useful as therapeutic agents in the treatment of CD276 positive cancers. Furthermore, the present invention provides antibody conjugates and bispecific antibodies developed based on the novel anti-CD276 antibodies of the present invention. Furthermore, the present invention discloses the therapeutic use of antibodies and other modulators in the treatment of CD276 positive cancers. Finally, nucleic acid constructs encoding the molecules of the present invention, recombinant cells expressing them, and specific uses and methods are provided.

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and / or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified Als3 (Agglutinin-like sequence 3 of Candida albicans) protein. The modified Als3 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Als 3 (Candida albicans lectin-like sequence 3) protein. The modified Als3 protein can be used as a carrier protein for other antigens, especially carbohydrate antigens or other antigens lacking T cell epitopes.

The present disclosure provides for antibody or antigen-binding fragments thereof that bind to human 4Ig-B7H3, multispecific antibody or antigen-binding fragments thereof that recognize human 4Ig-B7H3 as one antigen and at least one other antigen, anti-human 4Ig-B7H3 antibodies or antigen-binding fragments thereof further conjugated with a cytotoxin, a pharmaceutical composition comprising said antibodies or antigen-binding fragments thereof, and use of the antibody, multispecific antibody or the composition for treating a disease, such as cancer.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.

The application discloses an EB virus antigen of a chimeric design and application thereof. The EB virus chimeric antigen provided by the application is rationally designed based on structural biology, and gL, gH and gp42 proteins of an EB virus are connected through a linker. The antigen of the chimeric design simultaneously stably presents antigen epitopes of the three proteins, can increase the immunogenicity of a vaccine, and can simplify a production amplification process and quality control. The EB virus chimeric antigen can be used alone or in combination with other antigens, has high immunogenicity when used as a vaccine or a vaccine component, can induce an immune animal to produce a high level of neutralizing antibodies, can be used for preparing a vaccine for preventing or treating EB virus infection, and can be used as a detection reagent for the EB virus.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.

The application discloses a group B meningococcal fhbp V1.13 type subfamily monoclonal antibody and a preparation method and application thereof. The hybridoma cell strain is named as hybridoma cell strain V1.13-4E3-C12, and the preservation number is CCTCC NO: C202627. The fhbp V1.13 type monoclonal antibody secreted by the hybridoma cell strain has no cross reaction with fhbp V2 type and V3 type antibodies and other antigens and pathogens, has the advantages of high specificity and high sensitivity for detecting group B meningococcal fhbp V1.13 type protein. The application can be applied to the detection of fhbp V1.13 type protein antigen components in group B meningococcal vaccine, and can simultaneously identify fhbp V1.13 type protein antigen components in a multivalent group B meningococcal vaccine, detect antigen expression quantity, and detect the type of expressed target protein.

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.